Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Parry

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Genes|October 27, 2022
Robust Genetic Analysis of the X-Linked Anophthalmic (<i>Ie</i>) MouseBrianda A Hernandez-Moran, Andrew S Papanastasiou, David Parry, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Nature Communications|April 26, 2017
Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesisAmy T Y Yeung, Christine Hale, Amy H Lee, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Genome Biology|January 22, 2021
Minimal genome-wide human CRISPR-Cas9 libraryEmanuel Gonçalves, Mark Thomas, Fiona M Behan, et al.
Life Science Alliance|February 28, 2023
Regulatory de novo mutations underlying intellectual disabilityMatias G De Vas, Fanny Boulet, Shweta S Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Genes|October 27, 2022
Robust Genetic Analysis of the X-Linked Anophthalmic (<i>Ie</i>) MouseBrianda A Hernandez-Moran, Andrew S Papanastasiou, David Parry, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Nature Communications|April 26, 2017
Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesisAmy T Y Yeung, Christine Hale, Amy H Lee, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Genome Biology|January 22, 2021
Minimal genome-wide human CRISPR-Cas9 libraryEmanuel Gonçalves, Mark Thomas, Fiona M Behan, et al.
Life Science Alliance|February 28, 2023
Regulatory de novo mutations underlying intellectual disabilityMatias G De Vas, Fanny Boulet, Shweta S Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Pageof 11